Photo from wikipedia
The authors report results from the thyroid carcinoma cohort of the multicohort phase 2 KEYNOTE‐158 study (NCT02628067), which evaluated pembrolizumab monotherapy in patients with previously treated cancers. Click to show full abstract
The authors report results from the thyroid carcinoma cohort of the multicohort phase 2 KEYNOTE‐158 study (NCT02628067), which evaluated pembrolizumab monotherapy in patients with previously treated cancers.
Keywords:
keynote 158;
158 study;
phase keynote;
pembrolizumab monotherapy;
monotherapy patients
Journal Title: Cancer
Year Published: 2023
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Cancer
Year Published: 2023
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!